Literature DB >> 7430700

Natural resistance to methotrexate in human melanomas.

D W Kufe, M M Wick, H T Abelson.   

Abstract

Human melanomas are naturally resistant to methotrexate (MTX). The mechanism of intrinsic drug resistance has been explored in 3 melanoma cell lines not previously exposed to this agent. All 3 lines exhibited relative MTX resistance with ID50 values of greater than 1 microM. Drug uptake studies were performed over an extracellular concentration range of 0.1 to 10 microM MTX. The uptake was linear over the initial 10 min at all concentrations and subsequently reached plateau levels only at the 10 microM concentration. Lineweaver-Burke transformations yielded apparent Km (uptake) values of 1.4 to 5 microM, similar to data obtained from other human cell lines. The level of dihydrofolate reductase (DHFR) in the human melanoma cells ranged between 8.42 to 11.98 pmoles/mg protein. The melanoma DHFR levels are several fold higher than in MTX-sensitive human tumor lines and up to a hundred-fold higher than that measured in human brain tumor cells by our assay. The intrinsic resistance of these melanoma lines has therefore been attributed to elevated intracellular levels of DHFR.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7430700     DOI: 10.1111/1523-1747.ep12531146

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  4 in total

1.  Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines.

Authors:  Stefania Giudice; Luisa Benassi; Giorgia Bertazzoni; Eugenia Veratti; Daria Morini; Paola Azzoni; Maria P Costi; Alberto Venturelli; Silvia Pirondi; Stefania Seidenari; Cristina Magnoni
Journal:  Invest New Drugs       Date:  2011-09-01       Impact factor: 3.850

2.  The mechanism of differential sensitivity to methotrexate of normal and malignant human epidermal cells.

Authors:  M M Lee; J Ratliff; G B FitzGerald; M M Wick
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Suppression of antifolate resistance by targeting the myosin Va trafficking pathway in melanoma.

Authors:  María Piedad Fernández-Pérez; María F Montenegro; Magalí Sáez-Ayala; Luis Sánchez-del-Campo; Antonio Piñero-Madrona; Juan Cabezas-Herrera; José Neptuno Rodríguez-López
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

Review 4.  Targeting the epigenetic machinery of cancer cells.

Authors:  M F Montenegro; L Sánchez-del-Campo; M P Fernández-Pérez; M Sáez-Ayala; J Cabezas-Herrera; J N Rodríguez-López
Journal:  Oncogene       Date:  2014-01-27       Impact factor: 9.867

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.